Table 2:

Volume of injectate in patients experiencing transient neurologic adverse effects

Patient	Day 1 Volume (mL)	Day 2 Volume (mL)	Symptom/Sign
A	20	31^{^a}	Syncope
B	33	41^{^a}	Autonomic disturbance
C	26	41^{^a}	Altered mental status
D	21	41^{^a}	Autonomic disturbance
E	27^{^a}	52	Syncope
F	61^{^a}	31	Vertigo
G	43^{^a}	33	Altered mental status